Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

Breart B, Lemaître F, Celli S, Bousso P.

J Clin Invest. 2008 Apr;118(4):1390-7. doi: 10.1172/JCI34388.

2.

Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.

Rolle CE, Carrio R, Malek TR.

Cancer Res. 2008 Apr 15;68(8):2984-92. doi: 10.1158/0008-5472.CAN-07-3040.

3.

Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells.

Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ.

J Immunol. 2009 Aug 1;183(3):1828-37. doi: 10.4049/jimmunol.0802322. Epub 2009 Jul 10.

4.

Multiphoton imaging of cytotoxic T lymphocyte-mediated antitumor immune responses.

Boissonnas A, Scholer-Dahire A, Fetler L, Amigorena S.

Curr Top Microbiol Immunol. 2009;334:265-87. doi: 10.1007/978-3-540-93864-4_11. Review.

PMID:
19521689
5.

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Zhang B, Karrison T, Rowley DA, Schreiber H.

J Clin Invest. 2008 Apr;118(4):1398-404. doi: 10.1172/JCI33522.

6.

In vivo imaging of T cell delivery to tumors after adoptive transfer therapy.

Pittet MJ, Grimm J, Berger CR, Tamura T, Wojtkiewicz G, Nahrendorf M, Romero P, Swirski FK, Weissleder R.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12457-61. Epub 2007 Jul 18.

7.

Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H.

Cancer Res. 2008 Mar 1;68(5):1563-71. doi: 10.1158/0008-5472.CAN-07-5324.

8.

The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.

Riquelme E, Carreño LJ, González PA, Kalergis AM.

Eur J Immunol. 2009 Aug;39(8):2259-69. doi: 10.1002/eji.200939341.

9.

In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.

Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S.

J Exp Med. 2007 Feb 19;204(2):345-56. Epub 2007 Jan 29.

10.

Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes.

Bendle GM, Holler A, Pang LK, Hsu S, Krampera M, Simpson E, Stauss HJ.

Cancer Res. 2004 Nov 1;64(21):8052-6.

11.

[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].

Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.

Zhonghua Yi Xue Za Zhi. 2008 Jul 22;88(28):1956-60. Chinese.

PMID:
19062734
12.

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.

Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG.

J Immunother. 2008 Feb-Mar;31(2):132-47. doi: 10.1097/CJI.0b013e31815b69c8.

PMID:
18481383
13.

An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.

Marques CA, Hähnel PS, Wölfel C, Thaler S, Huber C, Theobald M, Schuler M.

Blood. 2008 Feb 1;111(3):1413-9. Epub 2007 Oct 30.

14.

Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.

Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.

Cancer Immunol Immunother. 2008 Sep;57(9):1357-65. doi: 10.1007/s00262-008-0471-z. Epub 2008 Feb 12.

PMID:
18265979
15.

Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.

Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S.

Oncol Rep. 2008 May;19(5):1265-70.

PMID:
18425386
16.

Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice.

Meunier MC, Baron C, Perreault C.

PLoS One. 2009;4(1):e4116. doi: 10.1371/journal.pone.0004116. Epub 2009 Jan 7.

17.

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.

Humar M, Maurer M, Azemar M, Groner B.

J Cancer Res Clin Oncol. 2009 Apr;135(4):567-80. doi: 10.1007/s00432-008-0491-2. Epub 2008 Oct 10.

PMID:
18846387
18.

In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.

Doubrovin MM, Doubrovina ES, Zanzonico P, Sadelain M, Larson SM, O'Reilly RJ.

Cancer Res. 2007 Dec 15;67(24):11959-69.

19.

Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.

Lee CH, Chiang YH, Chang SE, Chong CL, Cheng BM, Roffler SR.

Clin Cancer Res. 2009 Apr 15;15(8):2756-66. doi: 10.1158/1078-0432.CCR-08-2311. Epub 2009 Mar 24.

20.

Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.

Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS.

Int Immunol. 2009 Jun;21(6):655-65. doi: 10.1093/intimm/dxp034. Epub 2009 Apr 24.

Items per page

Supplemental Content

Write to the Help Desk